iBio (IBIO) Gross Margin (2020 - 2022)
iBio (IBIO) posted quarterly Gross Margin of 105.28% for Q1 2022, up 6972.0% year-over-year from 1.49% in Q1 2021, and down 48.28% quarter-over-quarter from 203.57% in Q3 2021.
iBio (IBIO) Gross Margin (2020 - 2022) Analysis & Trends
iBio (IBIO) has reported Gross Margin for 3 consecutive years, with 105.28% the latest figure, recorded in Q1 2022.
- In Q1 2022, Gross Margin rose 6972.0% year-over-year to 105.28%; the TTM figure through Jun 2022 stood at 115.02% (up 5711.0% YoY), while the FY2022 annual figure was 115.02%, up 7668.0% from the prior year.
- Gross Margin fell to 105.28% in Q1 2022 per IBIO's latest filing, from 203.57% in the prior quarter.
- Across five years, Gross Margin topped out at 203.57% in Q3 2021 and bottomed at 10.42% in Q1 2020.
- Historically, Gross Margin has averaged 79.25% across 3 years, with a median of 71.69% in 2020.
- On a YoY basis, Gross Margin climbed as much as 12967 bps in 2021 and fell as far as 1139 bps in 2021.
- iBio's Gross Margin stood at 70.07% in 2020, then surged by 191 bps to 203.57% in 2021, then tumbled by 48 bps to 105.28% in 2022.
- Business Quant data shows IBIO's Gross Margin at 105.28% in Q1 2022, 203.57% in Q3 2021, and 61.91% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 105.28% |
| Sep 30, 2021 | 203.57% |
| Jun 30, 2021 | 61.91% |
| Mar 31, 2021 | 35.56% |
| Dec 31, 2020 | 70.07% |
| Sep 30, 2020 | 73.90% |
| Jun 30, 2020 | 73.30% |
| Mar 31, 2020 | 10.42% |